利妥昔单抗治疗抗MuSK抗体阳性重症肌无力:多中心盲法前瞻性评价
这项多中心盲法前瞻性评价比较了抗MuSK抗体阳性重症肌无力患者接受利妥昔单抗与未接受利妥昔单抗的结局。主要终点MGSTI≤2在利妥昔单抗组达58%(14/24),对照组16%(5/31)(p=0.002),需治疗人数2.4。末次访视时利妥昔单抗组29%使用泼尼松(平均4.5 mg/天),对照组74%(平均13 mg/天)(p=0.001和p=0.005)。
要点
- 利妥昔单抗提高抗MuSK抗体阳性MG患者达到MGSTI≤2的概率。
- 利妥昔单抗组泼尼松使用比例和平均剂量均低于对照组。
- 证据等级为Class IV,需结合临床谨慎解读。
核心结论
- 对于抗MuSK抗体阳性重症肌无力患者,利妥昔单抗提高有利结局的概率。
研究设计与样本
- 多中心、盲法、前瞻性评价,比较接受与未接受利妥昔单抗的抗MuSK抗体阳性MG患者。
- 利妥昔单抗组24例,对照组31例,中位随访时间>3.5年。
主要发现
- 末次访视时,利妥昔单抗组58%(14/24)达到主要终点MGSTI≤2,对照组16%(5/31)(p=0.002)。
- 主要终点的需治疗人数为2.4。
- 末次访视时,利妥昔单抗组29%使用泼尼松(平均剂量4.5 mg/天),对照组74%(平均剂量13 mg/天)(p=0.001和p=0.005)。
关键数值与推荐
- 主要临床终点为MGSTI,结合MGFA干预后状态(PIS)与其他免疫抑制治疗的数量和剂量。
- 预先定义MGSTI≤2为有利结局。
- 次要结局包括改良MGFA PIS达轻微表现或更好、泼尼松平均/中位剂量及其他免疫抑制药物平均/中位剂量。
临床怎么用
- 对 anti-MuSK 抗体阳性MG患者,可考虑利妥昔单抗以提高有利结局概率并减少泼尼松用量。
- 治疗决策需结合Class IV证据等级和个体化评估。
局限性
- 证据等级为Class IV。
- 22例患者因随访不足被排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of rituximab in treatment of anti-muscle-specific kinase (MuSK) myasthenia gravis (MG). METHODS: This was a multicenter, blinded, prospective review, comparing anti-MuSK-positive patients with MG treated with rituximab to those not treated with rituximab. The primary clinical endpoint was the Myasthenia Gravis Status and Treatment Intensity (MGSTI), a novel outcome that combines the Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) and the number and dosages of other immunosuppressant therapies used. A priori, an MGSTI of level ≤2 was used to define a favorable outcome. Secondary outcomes included modified MGFA PIS of minimal manifestations or better, mean/median prednisone dose, and mean/median doses of other immunosuppressant drugs. RESULTS: Seventy-seven of 119 patients with anti-MuSK MG evaluated between January 1, 2005, and January 1, 2015, at 10 neuromuscular centers were selected for analysis after review of limited clinical data by a blinded expert panel. An additional 22 patients were excluded due to insufficient follow-up. Baseline characteristics were similar between the rituximab-treated patients (n = 24) and the controls (n = 31). Median follow-up duration was >3.5 years. At last visit, 58% (14/24) of rituximab-treated patients reached the primary outcome compared to 16% (5/31) of controls (p = 0.002). Number needed to treat for the primary outcome is 2.4. At last visit, 29% of rituximab-treated patients were taking prednisone (mean dose 4.5 mg/day) compared to 74% of controls (mean dose 13 mg/day) (p = 0.001 and p = 0.005). CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with anti-MuSK MG, rituximab increased the probability of a favorable outcome.
引用
- Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology. 2017. PMID: 28801338. doi:10.1212/WNL.0000000000004341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。